Expert Interviews

How oncology nurses can dismantle patient myths, secure early dietitian referrals, and collaborate to optimize supportive care like vitamin D.

Oncology clinical trial nurse navigator Elise Curry, RN, explains the impact of the FDA's approval of oral iberdomide for multiple myeloma.

Why first-line choices matter in metastatic TNBC: many miss second-line care, and new antibody-drug conjugates boost survival over chemo.

Oncology NPs discuss new frontline options for metastatic triple-negative breast cancer, using cases to guide therapy choice and manage toxicities.

A social worker explains how patient "difficulties" are often trauma-based fight, flight, freeze, or fawn responses to a health crisis.

Dr. Michael Wong discusses clinical workflows, dosing calculations, and biosafety protocols for the newly approved Tudriqev-nivolumab regimen.

A new study reveals global gaps in integrative oncology knowledge, highlighting communication and the role of APPs in community settings.

New Phase 3 ENDURANCE trial data shows no survival benefit for indefinite lenalidomide maintenance over 2 years in non-transplant myeloma patients.

Theresa Lynne Harrington Stukus, ANPBC NP, discusses managing the influx of new breast cancer therapies and the importance of professional networking.

Laura Cullen DNP, RN, FAAN discusses leadership and systems infrastructure ahead of her keynote at the Roswell Park Evidence-Based Practice Symposium.

Fumiko Chino, MD, discusses strategies for oncology nurses to address unproven treatments like ivermectin while maintaining patient trust.

Oncology dietitian Gabrielle Raucci explores the role of creatine in cancer care, highlighting when to use it and risks during active treatment.

The FDA has approved perioperative pembrolizumab and enfortumab vedotin for adult patients with muscle-invasive bladder cancer.

In the phase 3 RASolute 302 trial, oral KRAS inhibitor daraxonrasib nearly doubled median overall survival to 13.2 months in pancreatic cancer.

Stephanie Desrosiers discusses strategies for oncology nurses to manage chemotherapy shortages, ensuring patient safety, equity, and mental health.

NYU Langone experts discuss multidisciplinary care, diagnostic challenges, and nursing's role in treating rare bone and soft tissue sarcomas.

Drs. Sledge and Pastorini discuss how AI-powered molecular profiling corrected a misdiagnosis and the vital "early warning" role of oncology nurses.

FDA approves gedatolisib for HR+/HER2– breast cancer. Learn about the VIKTORIA-1 trial, dosing, and nursing strategies for managing stomatitis.

FDA approves SC isatuximab-irfc with the CirCLIQ on-body injector, streamlining multiple myeloma care and reducing nursing burden.

Donna Berizzi discusses how LeanTaaS capacity management tools reduce nurse burnout by optimizing outpatient workflows and improving patient access.

Dr. Rodney Haring discusses the 2026 AACR Cancer Disparities Report and the critical role of oncology navigators in tribal and rural health equity.

Oncology nurse Kerry Mann details the protocols and patient-centered strategies for bringing advanced precision medicine to local community clinics.

Maite San Miguel and a new survey highlight how specialized training and clinical autonomy are vital for optimizing multiple myeloma outcomes.

Oncology nurse Diane Stanaway offers essential sun protection strategies as NJ prepares for the heat of the 2026 World Cup and rising skin cancer rates.

Rita M. Jakubowski, NP, explains how multidisciplinary age-friendly assessments and the CHARM study improve outcomes for older transplant patients.

Diane Stanaway, MSN, RN, highlights the importance of long-term skin protection for oncology patients during high-exposure events like the World Cup.

Nicholas Hornstein, MD, PhD discusses ctDNA in colorectal cancer, the INTERCEPT-TT trial, building Northwell's GI oncology program, and what better drugs will look like.

Dr. Sriram Machineni explains why GLP-1 medications help manage cardiovascular health and inflammation in breast cancer survivorship.